China SXT Pharmaceuticals, Inc. (SXTC) income statement
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30
$2.83−0.03 (-1.05%)
Close on Nov 18, 2026Market cap $2.71MP/E –Yield –
China SXT Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, FY2026
- Gross margin
- 21.9%
- Operating margin
- -625.9%
- Net margin
- -545.2%
- Return on equity, FY2026
- -27.5%
Financial strength
- Current ratio
- 7.93
- Debt to equity
- 0.03
- Debt to assets
- 2.9%
- Cash to current liabilities
- 647.8%
Valuation
- P/E ratio
- –
- Price to sales
- 2.38
- Price to book
- 0.09
- Dividend yield
- –
See a number that looks wrong?